PCVX · Healthcare
Vaxcyte Inc
27/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
36
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$8.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About VAXCYTE INC
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein…
Who's behind the signal
Every informed buyer we can see on PCVX, across all three feeds.
Hedge funds · 6
Baupost Group (Klarman)
New position
Bridgewater Associates (Dalio)
New position
Point72 (Steve Cohen)
Increased +284%
AQR Capital Management
Increased +72%
D.E. Shaw & Co
Decreased −21%
Millennium Management (Englander)
Decreased −31%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
VAXCYTE INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
2
New positions
2
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.8×
% of portfolio
0.9%
Position change
NEW
0.9% of Baupost Group's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
NEW
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+284%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+72%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−21%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−31%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to VAXCYTE INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell VAXCYTE INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订